Incannex Healthcare

Update in progress

IXHL (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company based in Sydney, Australia. It develops psychedelic medicines and other therapies for chronic diseases. Its programs include IHL-42X, an oral fixed-dose combo of dronabinol and acetazolamide in Phase 2/3 for obstructive sleep apnea; PSX-001, an oral synthetic psilocybin in Phase 2b for generalized anxiety disorder; and IHL-675A, a fixed-dose cannabidiol plus hydroxychloroquine sulfate for rheumatoid arthritis and related lung and inflammatory conditions.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.16; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive